Clinical trial · no report yet · Phase 3
ElevateTN
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- NCT02475681 ↗
- Active not recruiting
- Acerta Pharma BV
- 131 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 68 | |
| Podcasts | 58 | |
| X threads | 4 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib; Obinutuzumab; Chlorambucil
- Arms
- Arm A - Obinutuzumab in Combination with Chlorambucil · Active comparator
- Arm B - Acalabrutinib in Combination with Obinutuzumab · Experimental
- Arm C - Acalabrutinib Monotherapy · Experimental
- Enrollment
- 535
- Primary outcomes
- Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B
- Sponsor
- Acerta Pharma BV
- Start
- Jun 26, 2015
- Primary completion
- Feb 8, 2019
- Results posted
- Yes
- Registry record
- NCT02475681 · updated Aug 25, 2026
Publications
linked from the registry- Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11;146(11):1276-1285. doi: 10.1182/blood.2024024476. PubMed 40198878
- Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong ASM, Fam F, Roos J, Shetty V, Skarbnik A, Davids MS. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 Jun 11;8(11):2861-2869. doi: 10.1182/bloodadvances.2023012142. PubMed 38598745
- Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. PubMed 32305093